GlassScriptPhysician profile
Chester Tung
NPI 1588907901
$3,115.71
in general payments reported to CMS, 2019-2025
26 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2022: $289 · 2023: $458 · 2024: $835 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $454.69 | 2022-2025 | Linzess, Viberzi, Creon |
| Astrazeneca Pharmaceuticals LP | $318.11 | 2019-2025 | Airsupra |
| Amgen INC. | $316.17 | 2022-2025 | Repatha, Otezla, Evenity |
| Aimmune Therapeutics, INC. | $285.93 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $263.76 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $262.09 | 2024-2025 | |
| Lilly USA, LLC | $184.83 | 2023-2025 | Jardiance, Mounjaro, Emgality |
| Nestle Healthcare Nutrition INC. | $139.35 | 2022-2023 | |
| Dexcom, INC. | $136.02 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $131.78 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $86.96 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.16 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $78.43 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $52.50 | 2019 | |
| Amarin Pharma, INC. | $46.33 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.52 | 2025 | Gardasil 9, Capvaxive, M-M-R II |
| Medtronic, INC. | $37.39 | 2024 | Intellis Adaptivestim |
| Mylan Specialty L.P. | $29.17 | 2024 | Yupelri |
| Oyster Point Pharma, INC. | $27.72 | 2022 | |
| Vivus LLC | $24.41 | 2025 | Pancreaze |
| Xeris Pharmaceuticals, INC. | $23.08 | 2023 | Gvoke Hypopen |
| Corcept Therapeutics | $22.51 | 2025 | Korlym |
| Ardelyx, INC. | $21.07 | 2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $19.53 | 2024 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $18.64 | 2023 | Linzess |
| Esperion Therapeutics, INC. | $17.56 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chester Tung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.